<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05066139</url>
  </required_header>
  <id_info>
    <org_study_id>2020-018</org_study_id>
    <secondary_id>2021-A00956-35</secondary_id>
    <nct_id>NCT05066139</nct_id>
  </id_info>
  <brief_title>Multidisciplinary Evaluation of Elderly Patients With Digestive Cancer (EPODIG-G)</brief_title>
  <acronym>EPODIG-G</acronym>
  <official_title>Monocentric Randomized Study Evaluating the Impact of an Early Multidisciplinary Program in Elderly Subjects Starting a Chemotherapy for Digestive Cancer: Multidisciplinary Evaluation of Elderly Patients With Digestive Cancer (EPODIG-G)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de cancérologie Strasbourg Europe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de cancérologie Strasbourg Europe</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a monocentric, comparative, open-label, randomized parallel group study enrolling&#xD;
      elderly subjects hospitalized in Strasbourg Europe Cancerology Institute (ICANS), starting&#xD;
      chemotherapy or targeted therapy for the treatment of digestive cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the ICANS an EPODIG-G program, consisting in a coordination of supportive care that are&#xD;
      existing in the Institute, is proposed to elderly patients with digestive cancer. The purpose&#xD;
      of this study is to evaluate the impact of this early multidisciplinary geriatric program&#xD;
      (EPODIG-G), when it is initiated before therapeutic treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2021</start_date>
  <completion_date type="Anticipated">September 17, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 17, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of EPODIG-G program on treatment.</measure>
    <time_frame>24 weeks after treatment initiation</time_frame>
    <description>Number of patients who benefit from all programmed treatment cycles at 24 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-intensity evaluation. Cumulative doses and theoretical doses of chemotherapy or targeted therapy.</measure>
    <time_frame>24 weeks after treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events and serious adverse events according to CTCAE v5.0.</measure>
    <time_frame>throughout treatment, at 8, 16 and 24 weeks after treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 years after last inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years after last inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Digestive System Disease</condition>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive standard care before treatment initiation (i.e. geriatric assessment only).&#xD;
Geriatric assessment includes: Mini Mental State Examination ; mini-Geriatric Depression Scale (mini-GDS) ; Body Mass Index (BMI) calculation ; Mini Nutritional Assessment (MNA) ; Time up and Go ; Cumulative Illness Rating Scale - Geriatric (CIRS-G) ; Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) questionnaires.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B Multidisciplinary EPODIG program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo the same geriatric assessment as in Arm A plus EPODIG-G program before treatment initiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EPODIG-G program (coordination of supportive care)</intervention_name>
    <description>EPODIG-G program includes: a nutritional evaluation (laboratory tests: albumin, pre-albumin, C reactive protein and vitamin D dosage, nutritional status, Handgrip test, Simple Evaluation of Food Intake (SEFI), spontaneous food intake evaluation) ; a medication reconciliation ; physical therapy (Six Minute Walk Test)</description>
    <arm_group_label>Arm B Multidisciplinary EPODIG program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be ≥ 75 years old&#xD;
&#xD;
          -  Performance status 0, 1 or 2&#xD;
&#xD;
          -  Diagnostic of digestive cancer, all stages (adjuvant or metastatic), with an&#xD;
             indication for chemotherapy treatment or targeted therapy&#xD;
&#xD;
          -  Patients previously treated with one or several lines of chemotherapy for this&#xD;
             digestive cancer are eligible&#xD;
&#xD;
          -  Estimated life expectancy ≥ 3 months&#xD;
&#xD;
          -  Patients able to speak, read and understand French&#xD;
&#xD;
          -  Signed informed consent from the patient&#xD;
&#xD;
          -  Patients must have a social security coverage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of differentiated neuroendocrine tumors grade 1 or 2 (pancreas, small&#xD;
             intestine)&#xD;
&#xD;
          -  History of another treated cancer during the last five years&#xD;
&#xD;
          -  History of major surgery and/or curative radiation therapy during the last 4 weeks&#xD;
             before inclusion&#xD;
&#xD;
          -  Patients unable to submit to medical follow-up for geographical, social or&#xD;
             psychological reasons&#xD;
&#xD;
          -  Patients placed under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Valérie SARTORI</last_name>
    <phone>368767223</phone>
    <phone_ext>33</phone_ext>
    <email>v.sartori@icans.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manon VOEGELIN</last_name>
    <phone>368767360</phone>
    <phone_ext>33</phone_ext>
    <email>promotion-rc@icans.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de cancérologie Strasbourg Europe</name>
      <address>
        <city>Strasbourg</city>
        <zip>67033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie SARTORI</last_name>
      <phone>368767223</phone>
      <phone_ext>33</phone_ext>
      <email>v.sartori@icans.eu</email>
    </contact>
    <contact_backup>
      <last_name>Manon VOEGELIN, PhD</last_name>
      <phone>368767360</phone>
      <phone_ext>33</phone_ext>
      <email>promotion-rc@icans.eu</email>
    </contact_backup>
    <investigator>
      <last_name>Meher BEN ABDELGHANI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damien HEITZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascale CHIAPPA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Virginie LEROY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Digestive cancer</keyword>
  <keyword>supportive care</keyword>
  <keyword>gastrointestinal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

